An Outcome Assessment of a Single Institution’s Longitudinal Experience with Uveal Melanoma Patients with Liver Metastasis

An Outcome Assessment of a Single Institution’s Longitudinal Experience with Uveal Melanoma Patients with Liver Metastasis

There is no FDA-approved treatment for metastatic uveal melanoma (UM) and overall outcomes are generally poor for those who develop liver metastasis. We performed a retrospective single-institution chart review on consecutive series of UM patients with liver metastasis who were treated at Thomas Jef...

Full description

Bibliographic Details
Main Authors: Rino S. Seedor, David J. Eschelman, Carin F. Gonsalves, Robert D. Adamo, Marlana Orloff, Anjum Amjad, Erin Sharpe-Mills, Inna Chervoneva, Carol L. Shields, Jerry A. Shields, Michael J. Mastrangelo, Takami Sato
Format: Article
Language:English
Published: MDPI AG 2020-01-01
Series:Cancers
Subjects:
uveal melanoma
metastatic uveal melanoma
liver metastasis
survival
treatment strategy
liver-directed treatment
real-world data
Online Access:https://www.mdpi.com/2072-6694/12/1/117

Internet

https://www.mdpi.com/2072-6694/12/1/117

Similar Items